Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Cristiana A Costa, DO, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd A MacKenzie, PhD, Anne W Beaven, MD, Frederick Lansigan, MD

Blood (2016) 128 (22): 1793.

https://doi.org/10.1182/blood.V128.22.1793.1793

Published: 2016

Journal Articles

Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma

Qiushi Chen, Turgay Ayer, PhD, Adam C Rose, Loretta J. Nastoupil, MD, Christopher R. Flowers, MD, MS

Blood (2013) 122 (21): 2923.

https://doi.org/10.1182/blood.V122.21.2923.2923

Published: 2013

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Christian W. Scholz, MD, Antonello Pinto, MD, Werner Linkesch, MD, Ola Linden, MD, Andreas Viardot, MD, Ulrich Keller, MD, Georg Hess, MD, Kristina Lerch, MD, Ferdinando Frigeri, MD, Manuela Arcamone, MD, Bernd Frericks, MD, Christiane Pott, MD, Antonio Pezzutto

Blood (2010) 116 (21): 593.

https://doi.org/10.1182/blood.V116.21.593.593

Published: 2010

Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Anton Hagenbeek, MD, PhD, John Radford, MD, Achiel Van Hoof, MD, Umberto Vitolo, MD, Ama Z.S. Rohatiner, MD, Gilles Salles, MD, PhD, Pierre Soubeyran, MD, PhD, Herve Tilly, MD, Angelika Bischof Delaloye, MD, Wim L.J. van Putten, MSc, Franck Morschhauser, MD, PhD

Blood (2010) 116 (21): 594.

https://doi.org/10.1182/blood.V116.21.594.594

Published: 2010

Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

Blood (2008) 112 (11): 2002.

https://doi.org/10.1182/blood.V112.11.2002.2002

Published: 2008

NARROW

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only